期刊文献+

前列腺癌细胞外泌体抑制成骨细胞分化 被引量:1

Prostate cancer exosomes inhibit osteoblast differentition
下载PDF
导出
摘要 目的:探讨前列腺癌细胞外泌体对成骨细胞分化的影响。方法:采用ExoQuick-TC试剂盒与超滤法结合分离纯化前列腺癌细胞系PC3的外泌体,通过电镜、外泌体蛋白标志物CD63进行鉴定。用纯化的前列腺癌细胞外泌体处理前成骨细胞,提取总RNA,采用荧光实时定量PCR检测早期成骨分化标志物Runx2、Osx和中期成骨分化标志物Alp的表达情况。此外利用碱性磷酸酶(alkaline phosphatase,ALP)染色、茜素红染色方法检测成骨分化情况。结果:前列腺癌细胞外泌体可以进入到前成骨细胞中,并且外泌体处理前成骨细胞后,与对照组相比,Alp、Runx2与Osx的表达量显著降低(P <0.05),染色结果显示成骨分化受抑制。结论:在前列腺癌中,前列腺癌细胞会分泌出外泌体作用于前成骨细胞,并抑制成骨细胞的分化。 Objective:This study aims to explore the effect of exosome of prostate cancer cells on the osteoblast differentiation.Methods:The ExoQuick-TC kit and ultrafiltration are adopted to isolate and purify exosomes from prostate cancer cell lines.The exosomes will be characterized by marker CD63,and observed through electron microscopy.Extract total RNA from pre-osteoblasts treated by exosomes of prostate cancer cells;then expressions of Osx,Runx2 and Alp were detected by real-time PCR.Osx and Runx2 are the biomarker of early osteogenic differentiation and Alp is the biomarker of metaphase osteogenic differentiation.Furthermore,osteogenic differentiation were ohserved by using ALP and ARS staining.Results:Prostate cancer cell exosomes can enter pre-osteoblasts.Compared to control cells,the expression of Osx,Runx2 and Alp are decreased in pre-osteoblasts cells treated with prostate cancer cell exosomes(P<0.05).The staining results showed that osteogenic differentiation was inhibited.Conclusion:Prostate cancer cells secrete exosomes that can act on pro-osteoblasts and inhibit osteoblast differentiation.
作者 田笑 金玉翠 马长艳 Tian Xiao;Jin Yucui;Ma Changyan(Department of Developmental Genetics,Nanjing Medical University,Nanjing 211166,China)
出处 《南京医科大学学报(自然科学版)》 CAS CSCD 北大核心 2019年第8期1167-1171,共5页 Journal of Nanjing Medical University(Natural Sciences)
基金 国家自然科学基金面上项目(81570804,81872389)
关键词 外泌体 前列腺癌 骨转移 exosome prostate cancer bone metastasis
  • 相关文献

参考文献2

二级参考文献32

  • 1王振林,王笑芳.血清前列腺特异性抗原与碱性磷酸酶测定在判断前列腺癌骨转移中的价值[J].中华男科学杂志,2005,11(11):825-827. 被引量:4
  • 2Roudier MP, Vesselle H, True LD, et al. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: The effect of bisphosphonate therapy on bone scintigraphy results, Clin Exp Metastasis, 2003, 20 ( 2 ) : 171-180.
  • 3Singer FR, Eyre DR. Using biochemical markers of bone turnover in clinical practice. Cleve Clin J Med, 2008, 75 (10): 739 -750.
  • 4Yi B, Williams PJ, Niewolna M, et al. Tumor-derived plateletderived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer.Cancer Res, 2002, 62(3): 917-923.
  • 5Drake MT, Clarke BL, Kholsa S. Bisphosphonates: Mechanism of action and role in clinical practice. Mayo Clin Proc, 2008, 83 (9) : 1032-1045.
  • 6Wada N, Fujisaki M, Ishii S, et al. Evaluation of bone metabolic markers in breast cancer with bone metastasis. Breast Cancer, 2001, 8(2) : 131-137.
  • 7Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: An autopsy study of 1589 patients. Hum Pathol, 2000, 31(5): 578-583.
  • 8Chen N, Ye XC, Chu K, et al. A secreted isoform of ErbB3 promotes osteoneetin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res, 2007, 67 (14) : 6544- 6548.
  • 9Bonfil RD, Chinni S, Fridman R, et al. Proteases, growth factors, chemokines, and the microenvironment in prostate cancer bone metastasis. Urol Oncol, 2007, 25(5) : 407-411.
  • 10Ye L, Kynaston HG, Jiang WG. Bone metastasis in prostate cancer: Molecular and cellular mechanisms (Review). Int J Mol Med, 2007, 20(1) : 103-111.

共引文献19

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部